Skip to main content

Table 3 Descriptives of IPF-AE patients never and ever treated with steroids and immunosuppressants before hospital admission

From: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach

Descriptives IPF-AE Never treated Ever treated  
Sex 15 male / 9 female 6 male / 6 female 9 male / 3 female p = 0.400
Age (years) 69.5 (52–82) 71.5 (52–80) 68 (52–82) p = 0.270
Smoking (p-y) 40 (0–110) 35 (0–60) 42.5 (0–110) p = 0.515
BMI 25.35 (17.6–32) 24.93 (22.49–31.2) 27.4 (17.6–32) p = 0.081
Emphysema 4 yes, 20 no 1 yes, 11 no 3 yes, 9 no p = 0.590
PH 4 yes, 6 no, 6 NA 3 yes, 6 no, 2 NA 3 yes, 4 no, 4 NA p = 1
FVC (lt) 2.01 (0.59–3.17) 1.9 (0.59–2.43) 2.52 (1.34–3.17) p = 0.056
FVC % predicted 63 (27.1–94) 53.15 (27.1–81.8) 65.1 (34.3–94) p = 0.646
FEV1 (lt) 1.57 (0.56–2.78) 1.43 (0.56–1.88) 1.86 (1.25–2.78) p = 0.055
FEV1 % predicted 60.6 (31.3–79) 53.5 (31.3–70.2) 70.2 (41.7–79) p = 0.074
TLC (lt) 3.21 (2.44–4.64) 2.84 (2.44–4.23) 4.04 (2.84–4.64) p = 0.007
TLC % predicted 57.2 (38.7–86.9) 52.2 (38.7–86.9) 57.5 (55.9–75) p = 0.101
DLCO (ml/min/mmHg) 2.68 (1.69–4.49) 2.68 (1.69–4.49) 3.13 (1.9–3.85) p = 0.619
DLCO % predicted 38.3 (19.6–54.3) 37.4 (19.6–54.3) 38.3 (24–38.9) p = 0.865
6MWD (meters) 272 (150–492) 271.5 (153–492) 272 (150–441) p = 0.932
Disease duration 43 (0–96) 49 (0–77) 34 (6–96) p = 0.744
Pattern of GGO in HRCT 5 peripheral, 8 multifocal, 8 diffuse, 3 NA 3 peripheral, 5 multifocal, 3 diffuse, 1 NA 2 peripheral, 3 multifocal, 5 diffuse, 2 NA p = 0.444
NIMV 2 0 2 p = 0.478
Mechanical ventilation 6 0 6 p = 0.014
LTOT 6 3 3 p = 0.640
PO2/fiO2 163.5 (66–314.29) 181.25 (116.6–266.6) 152.95 (66–314.29) p = 0.378
BAL performed 6 yes, 18 no 3 yes, 9 no 3 yes, 9 no p = 0.640
  1. Data are presented as median values
  2. IPF-AE idiopathic pulmonary fibrosis acute exacerbation; BMI body mass index; PH pulmonary hypertension; FVC (forced vital capacity); FEV 1 forced expiratory volume in first second; TLC total lung capacity; DLCO diffusing capacity of the lung in carbon monoxide; 6MWD six minute walking distance; NA not available; GGO ground-glass opacities; HRCT high resolution computerized tomography; NIMV non-invasive mechanical ventilation; LTOT long-term oxygen therapy; PO 2 arterial pressure of oxygen; fiO 2 fraction of inspired oxygen; BAL bronchoalveolar lavage